Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (Methimazole) administration

PACE - Pacing and Clinical Electrophysiology

Volumn 24, Issue 10, 2001, Pages 1575-1576

  Koh, Tat W ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Erythromycin; QT prolongation; Torsades de pointes

Indexed keywords

CARBIMAZOLE; DIGOXIN; ERYTHROMYCIN; FUROSEMIDE; THIAMAZOLE; WARFARIN;

AGED; ARTICLE; CASE REPORT; FEMALE; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HUMAN; HYPERTHYROIDISM; LIVER FUNCTION TEST; PHARMACODYNAMICS; PRESCRIPTION; QT INTERVAL; RISK ASSESSMENT; THYROID DISEASE; TORSADE DES POINTES; URINARY TRACT INFECTION;

EID: 0034776747     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2001.01575.x     Document Type: Article

References (6)

1. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes)
2. A review of erythromycin-induced malignant tachyarrhythmia - Torsade de pointes
3. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome
4. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome
5. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes
6. Torsade de pointes and marked QT prolongation in association with hypothyroidism